Advanced searches left 3/3

Metronomic therapy - ClinicalTrials.gov

Summarized by Plex Scholar
Last Updated: 11 March 2022

* If you want to update the article please login/register

A Maintenance Protocol of Sirolimus in Combination With Metronomic Chemotherapy in Children With High-Risk Solid Tumors

Following solid organ transplantation, pediatric palliative care with antiangiogenic metronomic chemotherapy, in the form of low-dose daily oral administration of etoposide and cyclophosphamide in conjunction with antiangiogenic agents, such as celecoxib, is effective and well tolerated in children with refractory solid tumors. Sirolimus is used orally in adults and children. The Pediatric Preclinical Testing Program conducted clinical trials of sirolimus as a single agent against an in vitro panel of pediatric cell lines, as well as in vitro pediatric tumor panels. Following the completion of "standard" therapy, the primary aim of the study is to increase the 2-year progression-free survival in children with high-risk solid tumors who are administered a maintenance regimen with continuous sirolimus administered on a backbone of metronomic chemotherapy, as compared to high-risk solid tumor patients treated with observation alone following completion of "standard" therapy.

Source link: https://clinicaltrials.gov/ct2/show/NCT04469530


Single-agent Capecitabine as Metronomic Chemotherapy in Locoregionally Advanced Head and Neck Squamous Cell Carcinoma (CMHN):A Phase III, Multicentre, Randomised Controlled Trial

The standard treatment for resectable locoregionally advanced squamous cell carcinoma of the head and neck is a combination of radical surgery plus radiotherapy or concurrent chemoradiotherapy. In addition, induction chemotherapy plus radical radiotherapy or simultaneous chemoradiotherapy is also indicated for locoregionally advanced squamous cell carcinoma of larynx and hypopharynx. Following the reference therapy, two retrospective studies showed that the use of orally administered fluorouracil drugs after the reference therapy had significant improvement in LAHNSCC's prognosis. In LAHNSCC, we began a random phase III study to investigate the efficiency and safety of the addition of metronomic capecitabine to the standard therapy.

Source link: https://clinicaltrials.gov/ct2/show/NCT05044117

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

Source Recommendations

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions